Levonorgestrel IUD
PreclinicalSmall molecule
BayerLevonorgestrel IUD is one of 27 small molecule programs targeting Contraception. It is currently in Preclinical.
1
Indications
8
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Contraception
#DrugCompanyPhaseTrials
1Jadelle
IItalian Network for Tumor Biotherapy Foundation
Approved
Tivicay
GSKApproved
Estrace
Novo NordiskApproved
Cytotec
PfizerApproved
Implanon
OOrganon and Co
Approved
Prometrium
FerringApproved
Advil
KKenvue Brands
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Ultram
WWim Janssens
Approved
Imdur
OOmnivium
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Contraception3 trials
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Levonorgestrel IUD. EMBL-EBI & Wellcome Sanger Institute.
- [4]